Pulse 探索 nav.journalClub 辩论趋势研究者期刊

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

首页探索 nav.journalClub 趋势

⌘+K

Research Paper | Synapse

January 27, 2026Supportive Care in Cancer0 citationsOpen Access

View Full Paper

Effectiveness and safety of pegylated filgrastim (Pelgraz®) for the prevention of febrile neutropenia during cancer chemotherapy in all-day practice in Germany

TST. SteinmetzPraxis für Hämatologie und Onkologie PJP. JungbergChemnitz University of Technology DGDagmar GuthHelios Vogtland Klinikum Plauen

Key Points

Evaluate the effectiveness and safety of pegfilgrastim for preventing febrile neutropenia during chemotherapy.
Examined pegfilgrastim treatment in clinical practice
Assessed patient outcomes regarding febrile neutropenia
Evaluated safety profiles of pegfilgrastim
Pegfilgrastim was effective in reducing instances of febrile neutropenia
Treatment showed a favorable safety profile
Results suggest high tolerability in practice settings

Abstract

Pegfilgrastim (Pelgraz®) treatment appeared to be effective and safe in all-day practice.

问 AI

Like

Bookmark

Share

View Full Paper

问 AI

Like

Bookmark

Share

View Full Paper

Cite This Study

Steinmetz et al. (Sun,) studied this question.

synapsesocial.com/papers/69785538ccb046adae51761d https://doi.org/https://doi.org/10.1007/s00520-026-10354-1